Issues in pediatric vaccine-preventable diseases in low- to middle-income countries

References

• Centers for disease control and prevention. Pertussis in other countries. 2015. Available from http://www.cdc.gov/pertussis/countries.html
   Google Scholar
• World Health Organization. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:385-400; PMID:20939150
   PubMedGoogle Scholar
• Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 2003; 22:628-34; PMID:12867839
   PubMed Web of Science ®Google Scholar
• Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, Tozzi AE, Van Damme P. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011; 11:557-70; PMID:21600850; http://dx.doi.org/10.1016/S1473-3099(11)70007-X
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13-5; PMID:21228763
   PubMedGoogle Scholar
• Centers for disease control and prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women–Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131-5; PMID:23425962
   PubMed Web of Science ®Google Scholar
• Lobzin YV, Babachenko IV, Shamsheva OV, Tetenkova AA, Bakhareva NV, Boitsov VP, Zvereva NN. Retrospective Study of the Clinical Epidemiological Characteristics of Pertussis in Infants Prior to Their First Vaccination in the Russian Federation. Infect Dis Ther 2015; 4:113-123; PMID:25663041
   PubMedGoogle Scholar
• IDsurv. Organization webpage. 2015. Available from http://idsurv.org/index.htm
   Google Scholar
• Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, Yewale VN, Bansal CP, Mehta PJ. Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years–India, 2014 and updates on immunization. Indian Pediatr 2014; 51:785-800; PMID:25362009; http://dx.doi.org/10.1007/s13312-014-0504-y
   PubMed Web of Science ®Google Scholar
• Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15:265-302; PMID:8174658
   PubMed Web of Science ®Google Scholar
• Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, Walter EB, Jackson LA, Englund JA, Edwards MS, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014; 311:1760-9; PMID:24794369; http://dx.doi.org/10.1001/jama.2014.3633
   PubMed Web of Science ®Google Scholar
• Shakib JH, Korgenski K, Sheng X, Varner MW, Pavia AT, Byington CL. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr 2013; 163:1422-6; PMID:23896191; http://dx.doi.org/10.1016/j.jpeds.2013.06.021
   PubMed Web of Science ®Google Scholar
• Zheteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revzina NV, Kissin D, Lewis PW, Yue X, Haber P, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012; 207:59.e1-7; PMID:22727350; http://dx.doi.org/10.1016/j.ajog.2012.05.006
   PubMed Web of Science ®Google Scholar
• Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, Chavez G. California pertussis epidemic, 2010. J Pediatr 2012; 161:1091-6; PMID:22819634; http://dx.doi.org/10.1016/j.jpeds.2012.05.041
   PubMed Web of Science ®Google Scholar
• Forsyth K, Plotkin S, Tan T, Wirsing von Konig CH. Strategies to decrease pertussis transmission to infants. Pediatrics 2015; 135:e1475-e1482; PMID:25963002; http://dx.doi.org/10.1542/peds.2014-3925
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal vaccines WHO position paper–2012. Wkly Epidemiol Rec 2012; 87:129-44; PMID:24340399
   PubMedGoogle Scholar
• World Health Organization. Pneumococcal conjugate vaccine for childhood immunization–WHO position paper. Wkly Epidemiol Rec 2007; 82:93-104; PMID:17380597
   PubMedGoogle Scholar
• Centers for disease control and prevention. Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000–2012. MMWR Morb Mortal Wkly Rep 2013; 62:308-11; PMID:23615674
   PubMed Web of Science ®Google Scholar
• Murray J, Agocs M, Serhan F, Singh S, Deloria-Knoll M, O'Brien K, Mwenda JM, Mihigo R, Oliveira L, Teleb N, et al. Global invasive bacterial vaccine-preventable diseases surveillance–2008–2014. MMWR Morb Mortal Wkly Rep 2014; 63:1159-62; PMID:25503919
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Manual for the surveillance of vaccine-preventable diseases. 2014. Available from http://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html
   Google Scholar
• Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 2007; 196:1346-54; PMID:17922399; http://dx.doi.org/10.1086/521626
   PubMed Web of Science ®Google Scholar
• Public Health England. Cumulative weekly number of reports of Invasive Pneumococcal Disease due to any of the seven serotypes in Prevenar 7™ : Persons aged >=5 Years in England and Wales by Epidemiological Year: July-June (2005- To Date). 2014. Available from http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/InPrevenar7/pneumo03Cummulativeweekly5INPrevenar7vacc/
   Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS Med 2014; 11:e1001657; PMID:24892763; http://dx.doi.org/10.1371/journal.pmed.1001657
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381:214-22; PMID:23158882; http://dx.doi.org/10.1016/S0140-6736(12)61854-6
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014; 2:464-71; PMID:24726406; http://dx.doi.org/10.1016/S2213-2600(14)70060-8
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A, Borys D, Goldblatt D, Scott JA. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1–4 years: a randomized controlled trial. PLoS One 2014; 9:e85459; PMID:24465570; http://dx.doi.org/10.1371/journal.pone.0085459
   PubMed Web of Science ®Google Scholar
• KEMRI. The Pneumococcal Conjugate Vaccine Impact Study (PCVIS). 2014. Available from http://kemri-wellcome.org/programme/pcvis-2/
   Google Scholar
• Saha SK, Naheed A, el Arifeen S, Islam M, Al Emran H, Amin R, Fatima K, Brooks WA, Breiman RF, Sack DA, et al. Surveillance for invasive Streptococcus pneumoniae disease among hospitalized children in Bangladesh: antimicrobial susceptibility and serotype distribution. Clin Infect Dis 2009; 48 Suppl 2:S75-S81; PMID:19191622; http://dx.doi.org/10.1086/596544
   PubMedGoogle Scholar
• Tatochenko V, Sidorenko S, Namazova-Baranova L, Mayanskiy N, Kulichenko T, Baranov A, Lobzin Y, Kharit S, Kozlov R, Andreeva I, et al. Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program. Expert Rev Vaccines 2014; 13:257-64; PMID:24350587; http://dx.doi.org/10.1586/14760584.2013.871205
   PubMed Web of Science ®Google Scholar
• Hanna-Wakim R, Chehab H, Mahfouz I, Nassar F, Baroud M, Shehab M, Pimentel G, Wasfy M, House B, Araj G, et al. Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon. Vaccine 2012; 30 Suppl 6:G11-G17; PMID:23228352; http://dx.doi.org/10.1016/j.vaccine.2012.07.020
   PubMedGoogle Scholar
• Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365-76; PMID:17046469; http://dx.doi.org/10.1016/S0140-6736(06)69561-5
   PubMed Web of Science ®Google Scholar
• Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008; 47:1458-67; PMID:18959494; http://dx.doi.org/10.1086/591196
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization, Vaccines and Biologicals: Measles. 2014. Available from http://www.who.int/immunization/diseases/measles/en/
   Google Scholar
• World Health Organization. Immunization, Vaccines and Biologicals: Rubella. 2014. Available from http://www.who.int/immunization/diseases/rubella/en/
   Google Scholar
• Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, Seward JF. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356:1121-9; PMID:17360990; http://dx.doi.org/10.1056/NEJMoa064040
   PubMed Web of Science ®Google Scholar
• Bayer O, Heininger U, Heiligensetzer C, von Kries R. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine 2007; 25:6655-60; PMID:17706845; http://dx.doi.org/10.1016/j.vaccine.2007.07.010
   PubMed Web of Science ®Google Scholar
• Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23:132-7; PMID:14872179; http://dx.doi.org/10.1097/01.inf.0000109287.97518.67
   PubMed Web of Science ®Google Scholar
• Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006; 25:12-8; PMID:16395096; http://dx.doi.org/10.1097/01.inf.0000195626.35239.58
   PubMed Web of Science ®Google Scholar
• Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile. Vaccine 2009; 27:6504-11; PMID:19665608; http://dx.doi.org/10.1016/j.vaccine.2009.07.076
   PubMed Web of Science ®Google Scholar
• Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-40; PMID:17585291
   PubMedGoogle Scholar
• STIKO. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch Institut. Epidemiol Bull 2010; 30:279-98.
   Google Scholar
• Spackova M, Wiese-Posselt M, Dehnert M, Matysiak-Klose D, Heininger U, Siedler A. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine 2010; 28:686-91; PMID:19874924; http://dx.doi.org/10.1016/j.vaccine.2009.10.086
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, LaRussa PS, Gershon AA. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011; 203:312-5; PMID:21208922; http://dx.doi.org/10.1093/infdis/jiq052
   PubMed Web of Science ®Google Scholar
• Bialek SR, Perella D, Zhang J, Mascola L, Viner K, Jackson C, Lopez AS, Watson B, Civen R. Impact of a routine two-dose varicella vaccination program on varicella epidemiology. Pediatrics 2013; 132:e1134-e1140; PMID:24101763; http://dx.doi.org/10.1542/peds.2013-0863
   PubMed Web of Science ®Google Scholar
• Klein NP, Fireman B, Yih WK, Lewis E, Kulldorff M, Ray P, Baxter R, Hambidge S, Nordin J, Naleway A, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1-e8; PMID:20587679; http://dx.doi.org/10.1542/peds.2010-0665
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Ackerson BK, Sy LS, Tran TN, Jones TL, Yao JF, Xie F, Cheetham TC, Saddier P. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656-61; PMID:19520201; http://dx.doi.org/10.1016/j.vaccine.2009.05.056
   PubMed Web of Science ®Google Scholar
• Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine 2014; 32:645-50; PMID:24374498; http://dx.doi.org/10.1016/j.vaccine.2013.12.011
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Policy statement-Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011; 128:630-2; PMID:21873692; http://dx.doi.org/10.1542/peds.2011-1968
   PubMed Web of Science ®Google Scholar
• STIKO. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch Institut. Epidemiol Bull 2012; 30:283-310.
   Google Scholar
• Streng A, Liese JG. Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella. Vaccine 2014; 32:897-900; PMID:24412300; http://dx.doi.org/10.1016/j.vaccine.2013.12.065
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rotavirus vaccines. WHO position paper - January 2013. Wkly Epidemiol Rec 2013; 88:49-64; PMID:23424730
   PubMedGoogle Scholar
• Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72; PMID:12737740; http://dx.doi.org/10.3201/eid0905.020562
   PubMed Web of Science ®Google Scholar
• World Health Organization. Estimated rotavirus deaths for children under 5 years of age, 2008. 2012. Available from http://www.who.int/immunization/monitoring_surveillance/burden/estimates/rotavirus/en/
   Google Scholar
• Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63; PMID:18037080; http://dx.doi.org/10.1016/S0140-6736(07)61744-9
   PubMed Web of Science ®Google Scholar
• Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27:5936-41; PMID:19679216; http://dx.doi.org/10.1016/j.vaccine.2009.07.098
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98; PMID:20107214; http://dx.doi.org/10.1056/NEJMoa0904797
   PubMed Web of Science ®Google Scholar
• Braeckman T, Van Herck K, Meyer N, Pircon JY, Soriano-Gabarro M, Heylen E, Zeller M, Azou M, Capiau H, De Koster J, et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012; 345:e4752; PMID:22875947; http://dx.doi.org/10.1136/bmj.e4752
   PubMed Web of Science ®Google Scholar
• Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, Lopez P, Macias-Parra M, Ortega-Barria E, Rivera-Medina DM, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9; PMID:18395579; http://dx.doi.org/10.1016/S0140-6736(08)60524-3
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/NEJMoa052434
   PubMed Web of Science ®Google Scholar
• Food and drug administration. RotaTeq clinical review. 2006. Available from http://www.fda.gov/cber/review/rotamer020306rp1.pdf
   Google Scholar
• Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007; 119:11-8; http://dx.doi.org/10.1542/peds.2006-2058
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33; PMID:16394299; http://dx.doi.org/10.1056/NEJMoa052664
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007; 11 Suppl 2:S29-S35; PMID:18162243; http://dx.doi.org/10.1016/S1201-9712(07)60019-8
   PubMedGoogle Scholar
• Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, et al. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine 2012; 30 Suppl 1:A79-A85; PMID:22520141; http://dx.doi.org/10.1016/j.vaccine.2012.01.022
   PubMedGoogle Scholar
• Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine 2012; 30 Suppl 1:A24-A29; PMID:22520132; http://dx.doi.org/10.1016/j.vaccine.2011.08.124
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, de Oliveira LH, Tate J, Orozco M, Mercado J, Gonzalez A, Malespin O, Amador JJ, Umana J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51; PMID:19491186; http://dx.doi.org/10.1001/jama.2009.756
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, de Oliveira LH, Umana J, Tate J, Lopman B, Sanchez E, Reyes M, Mercado J, Gonzalez A, et al. Duration of protection of pentavalent rotavirus vaccination in Nicaragua. Pediatrics 2012; 130:e365-e372; PMID:22753550; http://dx.doi.org/10.1542/peds.2011-3478
   PubMed Web of Science ®Google Scholar
• Mast TC, Khawaja S, Espinoza F, Paniagua M, Del Carmen LP, Cardellino A, Sanchez E. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr Infect Dis J 2011; 30:e209-e215; PMID:21768920; http://dx.doi.org/10.1097/INF.0b013e31822a8527
   PubMed Web of Science ®Google Scholar
• Becker-Dreps S, Paniagua M, Dominik R, Cao H, Shah NK, Morgan DR, Moreno G, Espinoza F. Changes in childhood diarrhea incidence in nicaragua following 3 years of universal infant rotavirus immunization. Pediatr Infect Dis J 2011; 30:243-7; PMID:20881511; http://dx.doi.org/10.1097/INF.0b013e3181f87ffe
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Delayed onset and diminished magnitude of rotavirus activity–United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:697-700; PMID:18583958
   PubMedGoogle Scholar
• Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TT, Maldonado YA, Spoulou V, Mast TC, Staat MA. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin 2011; 7:734-48; PMID:21734466; http://dx.doi.org/10.4161/hv.7.7.15511
   PubMed Web of Science ®Google Scholar
• European medicines agency. Rotarix™. Summary of Product Characteristics. 2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000639/WC500054789.pdf
   Google Scholar
• Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatr Infect Dis J 2006; 25:S42-S47; PMID:16397428; http://dx.doi.org/10.1097/01.inf.0000197565.45345.4e
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Setia S, Fair E, LeBaron CW, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-72; PMID:11207352; http://dx.doi.org/10.1056/NEJM200102223440804; Available from http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142304.pdf
   PubMed Web of Science ®Google Scholar
• Offit PA. The future of rotavirus vaccines. Semin Pediatr Infect Dis 2002; 13:190-5; PMID:12199615; http://dx.doi.org/10.1053/spid.2002.125862
   PubMedGoogle Scholar
• Centers for disease control and prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999; 48:1007; PMID:10577495
   PubMedGoogle Scholar
• Patel MM, Lopez-Collada VR, Bulhoes MM, de Oliveira LH, Bautista MA, Flannery B, Esparza-Aguilar M, Montenegro Renoiner EI, Luna-Cruz ME, Sato HK, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011; 364:2283-92; PMID:21675888; http://dx.doi.org/10.1056/NEJMoa1012952
   PubMed Web of Science ®Google Scholar
• Velázquez FR, Colindres RE, Grajales C, Hernandez MT, Mercadillo MG, Torres FJ, Cervantes-Apolinar M, DeAntonio-Suarez R, Ortega-Barria E, Blum M, et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012; 31:736-44; PMID:22695189; http://dx.doi.org/10.1097/INF.0b013e318253add3
   PubMed Web of Science ®Google Scholar
• Desai R, Parashar UD, Lopman B, de Oliveira LH, Clark AD, Sanderson CF, Tate JE, Matus CR, Andrus JK, Patel MM. Potential intussusception risk vs. health benefits from rotavirus vaccination in Latin America. Clin Infect Dis 2012; 54:1397-405; PMID:22431803; http://dx.doi.org/10.1093/cid/cis191
   PubMed Web of Science ®Google Scholar
• Food and drug administration. FDA Releases Final Study Results of a Mini-Sentinel Postlicensure Observational Study of Rotavirus Vaccines and Intussusception. 2013. Available from http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm356758.htm
   Google Scholar
• University of Nairobi. Ministry of health introduces Rotavirus vaccine in Kenya. 2014. Available from http://healthservices.uonbi.ac.ke/node/1966
   Google Scholar
• Nadel S. Prospects for eradication of meningococcal disease. Arch Dis Child 2012; 97:993-8; PMID:22984187; http://dx.doi.org/10.1136/archdischild-2012-302036
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs and future perspectives. Wkly Epidemiol Rec 2013; 88:129-36; PMID:23544241
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 Suppl 2:B51-B63; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-28; PMID:23515099
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011; 86:521-39; PMID:22128384
   PubMedGoogle Scholar
• Bousema JCM, Ruitenberg J. Need for optimisation of immunisation strategies targeting invasive meningococcal disease in the Netherlands. Int J Health Policy Manag 2015; 4:757-61; http://dx.doi.org/10.15171/ijhpm.2015.168
   PubMed Web of Science ®Google Scholar
• Joshi VS, Bajaj IB, Survase SA, Singhal RS, Kennedy JF. Meningococcal polysaccharide vaccines: A review. Carbohydr Polym 2009; 75:553-65; http://dx.doi.org/10.1016/j.carbpol.2008.09.032
   Web of Science ®Google Scholar
• Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010; 50 Suppl 2:S45-S53; PMID:20144016; http://dx.doi.org/10.1086/648964
   PubMed Web of Science ®Google Scholar
• Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011; 10:307-22; PMID:21434799; http://dx.doi.org/10.1586/erv.11.8
   PubMed Web of Science ®Google Scholar
• Food and drug administration. Vaccines, blood, biologics: Menactra. 2013. Available from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm176044.htm
   Google Scholar
• European medicines agency. Menveo EPAR Product Information. 2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001095/WC500090147.pdf
   Google Scholar
• European medicines agency. Nimenrix EPAR. 2014. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002226/human_med_001548.jsp&mid=WC0b01ac058001d124
   Google Scholar
• European medicines agency. Bexsero. EPAR Product Information. 2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002333/WC500137881.pdf
   Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol 2012; 799:1-20; PMID:21993636; http://dx.doi.org/10.1007/978-1-61779-346-2_1
   PubMedGoogle Scholar
• Lingappa JR, Al Rabeah AM, Hajjeh R, Mustafa T, Fatani A, Al Bassam T, Badukhan A, Turkistani A, Makki S, Al Hamdan N, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9:665-71; PMID:12781005; http://dx.doi.org/10.3201/eid0906.020565
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Anis S, Htun-Myint L, Pawinski R, Soriano-Gabarro M, Vyse A. Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. Int J Infect Dis 2012; 16:e574-e582; PMID:22647750; http://dx.doi.org/10.1016/j.ijid.2012.03.011
   PubMed Web of Science ®Google Scholar